Jol J A D, van Velthuysen M L F, Hilgers F J M, Keus R B, Neering H, Balm A J M
Department of Otolaryngology/Head and Neck Oncology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Eur J Surg Oncol. 2003 Feb;29(1):81-6. doi: 10.1053/ejso.2002.1330.
To investigate the results of our treatment policy, we present our institutional experience in the management of regional neck node metastases of cutaneous head and neck squamous cell carcinoma (CHNSCC).
Between 1977 and 1997, 343 patients presented with CHNSCC, of whom 41 were treated for regional metastases, with parotidectomy and/or (selective) neck dissection. Histological analysis was performed on all operation specimens. Patients with multiple nodes and/or extra capsular rupture, at risk for recurrence, received adjuvant radiotherapy.
Seventy-six percent of the regional metastases occurred within the first 2 years, but a delay of more than 5 years was also observed. Parotid gland (56%), neck levels II (39%) and V (22%) were most frequently involved. Twenty-four percent of patients treated with curative intent failed at the regional site. Five years overall survival was 46%, with a median survival of 49 months. No survival differences emerged between patients treated by surgery alone and patients receiving adjuvant radiotherapy (P=0.14). Five patients died of disease, of whom three with distant metastases.
Regionally metastasized CHNSCC is a serious disease with a high risk of regional recurrence, calling for combined surgery and adjuvant radiotherapy. A small subset of patients with a long interval between completion of primary treatment and presence of regional nodes justifies a long follow-up.
为了研究我们的治疗策略效果,我们介绍了我们机构在治疗头颈部皮肤鳞状细胞癌(CHNSCC)区域淋巴结转移方面的经验。
1977年至1997年间,343例患者被诊断为CHNSCC,其中41例因区域转移接受了腮腺切除术和/或(选择性)颈部清扫术治疗。对所有手术标本进行了组织学分析。有多个淋巴结和/或包膜外破裂、有复发风险的患者接受了辅助放疗。
76%的区域转移发生在头两年内,但也观察到有超过5年的延迟情况。腮腺(56%)、颈部II区(39%)和V区(22%)是最常受累的部位。接受根治性治疗的患者中有24%在区域部位出现复发。5年总生存率为46%,中位生存期为49个月。单纯手术治疗的患者与接受辅助放疗的患者之间未出现生存差异(P=0.14)。5例患者死于该疾病,其中3例有远处转移。
区域转移的CHNSCC是一种严重疾病,区域复发风险高,需要联合手术和辅助放疗。一小部分在原发治疗完成与区域淋巴结出现之间间隔时间较长的患者需要进行长期随访。